Fundraising FoxCure Ventures — Full Portfolio
27 tracked investments · listed companies and verified rows first
Tasca Therapeutics develops novel cancer therapies using mass spectrometry-based proteomics to identify cancer-causing proteins with auto-palmitoylation modifications, targeting previously unknown binding pockets for difficult-to-treat cancers.
BiotechHealthtechMedical DevicesBoston, US
Dr. Milenko Cicmil(Co-founder & CEO)inDr. David Fisher(Co-founder)Dr. Xu Wu(Co-founder)Duojia Pan(Co-founder)
Alessa Therapeutics develops a proprietary drug-delivery platform for sustained and localized release of therapies to treat early-stage prostate cancer.
BiotechHealthtechMedical DevicesSan Carlos, US
Pamela Munster(Founder, Director & Chief Scientific Advisor)inCam Gallagher(President & Chief Executive Officer)inJohn Maroney(Executive Officer, Director)in
BoardZachary Collins(Executive Officer)inSteve Tregay(Director)in
Board seatAnnie Mitsak· per SEC Form D
Co-investorsMission Bay CapitalMission Biocapital
BiotechBoston, US
Ronald D. Seidel, III(Executive Officer, Director)David Fallace(Director)
BoardCameron Gallagher(Director)Rodolfo Chaparro(Director)inAndrew King(Executive Officer)in
Board seatDavid FallaceLou Tartaglia· per SEC Form D
Aevum develops therapeutic molecules derived from exercise to treat disease.
BiotechLongevity
Clasp Therapeutics develops off-the-shelf precision T cell engagers (its proprietary pHLАre molecules) that target mutant peptide-HLA complexes displayed on cancer cells, directing T cells to destroy tumors carrying common driver mutations such as KRas.
BiotechHealthtechCambridge, US
Co-investorsCatalio Capital Management, LPVivo CapitalBrightEdgeCatalio Capital ManagementNovo HoldingsThird Rock Ventures
Kenai Therapeutics develops iPSC-derived cell therapies and gene-modified medicines for neurodegenerative diseases, particularly Parkinson's disease, leveraging induced pluripotent stem cell technology to replace damaged neurons and restore neural function.
BiotechDeep TechHealthtechMedical Devices
Howard Federoff(Scientific Co-Founder, Chief Medical Officer and Executive Vice President of Corporate Medicine and Science)in
Co-investorsThe Column Group
Kobuk Therapeutics is developing a biologics platform aimed at treating autoimmune diseases by resetting the immune system to a healthy state while preserving protective immunity.
BiotechHealthtech
Permeasis Therapeutics is developing a Membrane Translocation Domain (MTD) platform that enables intracellular delivery of proteins and other large therapeutic macromolecules to the cytosol and intracellular compartments.
BiotechDeep TechBoston, US
Recuro is a virtual-first digital health platform that provides primary care, behavioral health, urgent care, and supplemental benefits (pharmacy, care management, advocacy) to patients, employers, health plans, and providers.
Digital HealthHealthtechSaaSRichardson, US
Michael Brombach(Chief Executive Officer and Co-Founder)inMichael Gorton(Chief Executive Officer)inDr. Kate Sowerwine(Chief Medical Officer)John Halsey(Director)Kris Engskov(Director)inWilliam Paiva(Director)
Co-investors1843 Capital4D CapitalARCH Venture PartnersCortado VenturesDeepWork CapitalGlobal Insurance Accelerator+5 more
Tortugas Neuro is a neuroscience drug development company focused on the neurology and neuropsychiatry space, working to advance clinical-stage therapies for brain health.
BiotechHealthtech
Co-investorsAN Venture PartnersThe Column Group
Triton Therapeutics is a clinical-stage biotechnology company developing first-in-class medicines for autoimmune and fibrotic diseases.
BiotechHealthtechStamford, US
BoardAnnie Mitsak(Director)inTimothy Shannon(Director)Elena Grigoryeva(Director)Paul Fonteyne(Executive Officer, Director)in
Co-investorsCanaan Partners
XenImmune is an immuno-oncology company developing first-in-class molecules that apply the biology of organ transplant hyperacute rejection to fight cancer by "painting" tumors with foreign blood groups to trigger anti-tumor immune responses.
BiotechHealthtechCambridge, US
Richard J. Lim(Chief Executive Officer)in
Crosslink Therapeutics develops protein engineering and cancer therapies, focusing on immunological and oncology treatments in the biopharmaceutical sector.
BiotechHealthtechMedical Devices
Ron Seidel(Co-founder and CEO)Rodolfo Chaparro(Co-founder and Scientific Advisor)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
RYNE Biotechnology Inc.Tasca TherapeuticsAevumAevum TherapeuticsCrosslinkDuneKenai TherapeuticsKobukKobuk TherapeuticsRecuroTascaTortugasTortugas NeuroscienceUnnamed antibody-enzyme fusion company
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.